[1] Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates[J]. Eur Urol, 2020, 77(1):38-52. DOI: 10.1016/j.eururo.2019.08.005.
[2] Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2024, 86(2):148-163. DOI: 10.1016/j.eururo.2024.03.027.
[3] Kord E, Flores JP, Posielski N, et al. Patient reported outcomes and health related quality of life in localized prostate cancer: a review of current evidence[J]. Urol Oncol, 2022, 40(7):304-314. DOI: 10.1016/j.urolonc.2022.04.008.
[4] Gartrell BA, Phalguni A, Bajko P, et al. Influential factors impacting treatment decision-making and decision regret in patients with localized or locally advanced prostate cancer: a systematic literature review[J]. Eur Urol Oncol, 2024, 7(6):1216-1227. DOI: 10.1016/j.euo.2024.04.016.
[5] 张颖,乔文博,李雅琴,等.决策辅助工具在前列腺癌患者中的应用进展[J].护理与康复,2023,22(8):75-79.DOI:10.3969/j.issn.1671-9875.2023.08.020.
[6] Baptista S, Teles Sampaio E, Heleno B, et al. Web-based versus usual care and other formats of decision aids to support prostate cancer screening decisions: systematic review and meta-analysis[J]. J Med Internet Res, 2018, 20(6):e228. DOI: 10.2196/jmir.9070.
[7] Todio E, Sharp J, Morrow A, et al. Examining the effectiveness and implementation of patient treatment decision-aid tools for men with localised prostate cancer: a systematic review[J]. Psychooncology, 2023, 32(4):469-491. DOI: 10.1002/pon.6094.
[8] Berry DL, Halpenny B, Hong F, et al. The personal patient profile-prostate decision support for men with localized prostate cancer: a multi-center randomized trial[J]. Urol Oncol, 2013, 31(7):1012-1021. DOI: 10.1016/j.urolonc.2011.10.004.
[9] Berry DL, Hong F, Blonquist TM, et al. Decision support with the personal patient profile-prostate: a multicenter randomized trial[J]. J Urol, 2018, 199(1):89-97. DOI: 10.1016/j.juro.2017.07.076.
[10] Berry DL, Hong F, Blonquist TM, et al. Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: results from a multi-site randomized trial[J]. Urol Oncol, 2021, 39(8):493.e9-493.e15. DOI: 10.1016/j.urolonc.2020.11.038.
[11] Thurtle D, Jenkins V, Freeman A, et al. Clinical impact of the predict prostate risk communication tool in men newly diagnosed with nonmetastatic prostate cancer: a multicentre randomised controlled trial[J]. Eur Urol, 2021, 80(5):661-669. DOI: 10.1016/j.eururo.2021.08.001.
[12] Cuypers M, Lamers RED, Kil PJM, et al. Impact of a web-based prostate cancer treatment decision aid on patient-reported decision process parameters: results from the prostate cancer patient centered care trial[J]. Support Care Cancer, 2018, 26(11):3739-3748. DOI: 10.1007/s00520-018-4236-8.
[13] Cuypers M, Lamers RED, Kil PJM, et al. Longitudinal regret and information satisfaction after deciding on treatment for localized prostate cancer with or without a decision aid. Results at one-year follow-up in the PCPCC trial[J]. Patient Educ Couns, 2019, 102(3):424-428. DOI: 10.1016/j.pec.2018.10.006.
[14] Lamers RED, Cuypers M, de Vries M, et al. Differences in treatment choices between prostate cancer patients using a decision aid and patients receiving care as usual: results from a randomized controlled trial[J]. World J Urol, 2021, 39(12):4327-4333. DOI: 10.1007/s00345-021-03782-7.
[15] Davison BJ, Goldenberg SL, Wiens KP, et al. Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer[J]. Cancer Nurs, 2007, 30(5):E7-E15. DOI: 10.1097/01.NCC.0000290819.22195.d6.
[16] Politi MC, Forcino RC, Parrish K, et al. The impact of adding cost information to a conversation aid to support shared decision making about low-risk prostate cancer treatment: results of a stepped-wedge cluster randomised trial[J]. Health Expect, 2023, 26(5):2023-2039. DOI: 10.1111/hex.13810.
[17] Diefenbach MA, Mohamed NE, Butz BP, et al. Acceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot study[J]. J Med Internet Res, 2012, 14(1):e6. DOI: 10.2196/jmir.1891.
[18] Diefenbach MA, Benedict C, Miller SM, et al. Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT[J]. Transl Behav Med, 2018, 8(6):876-886. DOI: 10.1093/tbm/iby066.
[19] Jayadevappa R, Chhatre S, Gallo JJ, et al. Patient-centered preference assessment to improve satisfaction with care among patients with localized prostate cancer: a randomized controlled trial[J]. J Clin Oncol, 2019, 37(12):964-973. DOI: 10.1200/JCO.18.01091.
[20] Joyce DD, Tilburt JC, Pacyna JE, et al. The impact of within-consultation and preconsultation decision aids for localized prostate cancer on patient knowledge: results of a patient-level randomized trial[J]. Urology, 2023, 175:90-95. DOI: 10.1016/j.urology.2023.02.029.
[21] Scherr KA, Fagerlin A, Hofer T, et al. Physician recommendations trump patient preferences in prostate cancer treatment decisions[J]. Med Decis Making, 2017, 37(1):56-69. DOI: 10.1177/0272989X16662841.
[22] 蔡欣旸,范宇,李永红.前列腺癌主动监测的研究进展[J].中华泌尿外科杂志,2024,45(6):477-480.DOI:10.3760/cma.j.cn112330-20240110-00019.
[23] Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer[J]. N Engl J Med, 2023, 388(17):1547-1558. DOI: 10.1056/NEJMoa2214122.
[24] 邵金鹏,宋勇,孙圣坤,等.前列腺偶发癌的病理特征及不同治疗方式的预后分析[J].中华泌尿外科杂志,2024,45(2):98-102.DOI:10.3760/cma.j.cn112330-20221228-00684.
[25] 罗云,周祥福.2021版美国国立综合癌症网络前列腺癌临床实践指南述评[J/OL].中华腔镜泌尿外科杂志(电子版),2022,16(1):1-6[2024-10-03].https://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhqjmnwkzz202201001.DOI:10.3877/cma.j.issn.1674- 3253.2022.01.001.
[26] 吴贤群,罗彩凤,吕妃,等.决策辅助工具在局限性前列腺癌患者治疗中应用效果的系统评价[J].中国性科学,2024,33(8):44-48.DOI:10.3969/j.issn.1672-1993.2024.08.010.
|